A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naive Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9

Trial Profile

A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naive Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Aluminium hydroxide; Meningococcal vaccine group B
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 28 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network, 7297)
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top